3dGRO^® Human Breast Organoids (DS115T)

Triple-negative breast cancer (TNBC) patient-derived organoids (PDOs) are advanced 3D in-vitro models that accurately recapitulate the genetic, phenotypic, and functional characteristics of TNBC tumors. TNBC is an aggressive and heterogeneous breast cancer subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 amplification, making it unresponsive to endocrine and HER2-targeted therapies. TNBC PDOs are established from patient tumor biopsies or resections and cultured in an extracellular matrix (ECM)-rich environment using optimized organoid media. TNBC PDOs provide a physiologically relevant alternative to 2D cultures and PDX models, retaining key tumor hallmarks such as high proliferation, Intratumoral Heterogeneity (ITH), invasiveness, genomic instability, and therapy resistance. Intratumoral heterogeneity in these organoid models enable accurate tumor modeling, drug response prediction, and biomarker discovery for advanced screening and personalized medicine.

Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide, making up around 32% of all new cancer cases. BC includes over 21 distinct histological subtypes and four major molecular subtypes: Luminal A, Luminal B, HER2-positive, and the highly aggressive TNBC subtype. TNBC is a subtype of invasive ductal carcinoma (IDC), a prevalent type of BC, and represents approximately 10-20% of all BC cases. TNBC comprises several distinct molecular subtypes, each with unique biological characteristics and clinical implications:

Basal-like (BL1 and BL2): These subtypes show elevated expression of genes involved in DNA damage repair and cell cycle regulation, often indicating an increased sensitivity to DNA-damaging therapies.

• Mesenchymal (M) and Mesenchymal Stem-like (MSL): Defined by high expression of genes associated with epithelial-mesenchymal transition (EMT) and growth factor signaling, these subtypes are often linked to increased metastasis and poor prognosis.
• Luminal Androgen Receptor (LAR): Characterized by prominent androgen receptor signaling, the LAR subtype may respond to androgen receptor-targeted therapies, offering potential therapeutic avenues.
• Basal-like Immunosuppressed (BLIS): This subtype is marked by chromosomal instability and a homologous recombination deficiency (HRD) mutation signature, highlighting the potential for targeted therapies based on DNA repair mechanisms.
• Basal-like Immune-Activated (BLIA): In contrast to BLIS, BLIA shows better clinical outcomes, likely due to immune activation within the tumor microenvironment.

• The 3dGRO^® Triple-Negative Breast Cancer (TNBC) Organoid biobank offers a selection of patient-derived TNBC organoids, for advanced disease modeling research. This biobank includes highly characterized organoid lines from different donors, representing basal-like metastatic TNBCs (BL-mTNBCs). Our organoid lines exhibit expression of both basal and luminal markers, highlighting their molecular heterogeneity and luminal progenitor lineage.

Cell Line Characteristics

• Sex: Female
• Age: 58 Years
• Race: Hispanic/Latino
• Organ: Breast (Primary Tumor).
• Disease: Triple-Negative (ER-/ PR-/ HER2-) Invasive Ductal Carcinoma (Grade 3)

Cryopreserved patient derived triple-negative (ER-, PR-, HER2-) breast tumor organoids (PDOs).

Store in liquid nitrogen. The organoids can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

3dGRO^® is a trademark of Merck KGaA, Darmstadt, Germany.
3dGRO^® organoids were derived utilizing HUB Organoid Technology.

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/pdouse. This product may not be re-engineered or copied; used to make derivatives or modifications; used to develop, test, or manufacture a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact organoids@milliporesigma.com.

3dGRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.